Sanofi Plummets 2.3% Amid Double Setback for MS Drug Tolebrutinib and Regulatory Delays

Summary
• Sanofi’s shares nosedive 2.29% intraday, trading at $47.57 amid a $1.7B partnership with Dren Bio and regulatory setbacks for its MS drug.
• The stock breaches its 52-week low of $44.62, with Bollinger Bands signaling oversold conditions at $47.44.
• A $1.7B deal with Dren Bio for multispecific antibody therapies contrasts with a failed Phase III trial for tolebrutinib in PPMS.
•
Sanofi’s stock faces a perfect storm of clinical and regulatory headwinds, with a 6% intraday drop compounding sector-wide volatility. The pharma giant’s strategic pivot to autoimmune therapies clashes with immediate setbacks in its MS pipeline, testing investor confidence in its long-term growth narrative.

Double Setback for Tolebrutinib Sparks Investor Flight
Sanofi’s stock collapsed following two critical blows to its MS drug pipeline. First, the FDA delayed the review of tolebrutinib for non-relapsing secondary progressive MS (nrSPMS) to Q1 2026, pushing back a decision by three months. Simultaneously, the drug failed its Phase III trial in primary progressive MS (PPMS), a smaller but lucrative market. These setbacks, coupled with ongoing concerns about drug-induced liver injury, have eroded confidence in tolebrutinib’s commercial potential. The stock’s 2.29% drop reflects immediate fears of delayed revenue streams and regulatory uncertainty, despite the $1.7B partnership with Dren Bio for autoimmune therapies.

Pharma Sector Mixed as Merck Gains 0.38%
The broader pharmaceutical sector remains fragmented, with Merck (MRK) bucking the trend by rising 0.37% on positive oncology data. Sanofi’s struggles highlight the sector’s vulnerability to clinical trial outcomes and regulatory delays. While Merck’s growth in immunology and vaccines offers a counterpoint, Sanofi’s reliance on high-risk MS therapies underscores the sector’s exposure to R&D volatility. Investors are now scrutinizing pharma giants’ pipeline diversity, with Sanofi’s pivot to autoimmune diseases facing immediate skepticism.

Bearish Setup: Put Options and ETFs for Short-Term Volatility
• Technical Indicators: 200-day MA: $50.56 (above), RSI: 42.88 (oversold), MACD: -0.42 (bearish), Bollinger Bands: $47.44 (lower band).
•
Sanofi’s technicals signal a short-term bearish bias, with the stock trading near its 52-week low and key support levels at $48.82 (30D) and $49.66 (200D). The RSI at 42.88 suggests oversold conditions, but the MACD histogram (-0.16) and negative 200-day crossover confirm downward momentum. Traders should monitor the $46.97 intraday low as a critical breakdown level.
•
Top Put Option: SNY20251219P47.5
• Contract Code: SNY20251219P47.5
• Type: Put
• Strike Price: $47.50
• Expiration: 2025-12-19
• IV: 33.80% (moderate)
• LVR: 68.01% (high)
• Delta: -0.47 (moderate sensitivity)
• Theta: -0.0865 (high time decay)
• Gamma: 0.21 (high sensitivity to price swings)
• Turnover: 9,235 (liquid)
•
This put option offers a high leverage ratio (68%) and gamma (0.21), ideal for a 5% downside scenario. A 5% drop to $45.18 would yield a payoff of $2.32 per contract, with theta decay amplifying gains as expiration nears.
•
Top Put Option: SNY20260116P47.5
• Contract Code: SNY20260116P47.5
• Type: Put
• Strike Price: $47.50
• Expiration: 2026-01-16
• IV: 22.77% (low)
• LVR: 38.08% (moderate)
• Delta: -0.47 (moderate sensitivity)
• Theta: -0.0207 (low time decay)
• Gamma: 0.12 (moderate sensitivity)
• Turnover: 146,289 (highly liquid)
•
This longer-dated put provides a safer play with lower theta decay, allowing time for the stock to retest support levels. A 5% drop would yield a $2.32 payoff, with the 200-day MA acting as a psychological barrier.
•
Action: Aggressive bears target SNY20251219P47.5 for a 5% downside, while conservative traders use SNY20260116P47.5 to hedge against prolonged weakness.

Backtest Sanofi Stock Performance
Sanofi (SNY) has experienced a total of 488 intraday percentage changes of -2% or more from 2022 to the present. While the 3-day win rate is 52.25%, the 10-day win rate is 56.15%, and the 30-day win rate is 51.23%, indicating a higher probability of positive returns in the short term, the overall performance after such events has been relatively modest, with a maximum return of only 1.08% over 30 days. This suggests that while Sanofi has shown resilience in the face of significant intraday declines, its performance in the subsequent days has generally been muted.

Sanofi at Crossroads: Watch $46.97 Breakdown and Merck’s Lead
Sanofi’s near-term outlook hinges on whether the $46.97 intraday low holds as a support level. A breakdown would validate the bearish case, with the 52-week low of $44.62 as the next target. The $1.7B Dren Bio partnership offers long-term upside, but immediate focus remains on the MS pipeline’s credibility. Investors should monitor Merck’s 0.38% gain as a sector barometer, with Merck’s strength in oncology contrasting Sanofi’s struggles. For now, short-term volatility favors put options, while a rebound above $48.82 could reignite bullish sentiment. Watch for $46.97 breakdown or Merck’s momentum shift.